Monte Rosa Therapeutics (NASDAQ:GLUE) Trading 7.4% Higher on Analyst UpgradeMarket Beat·1 hour agoGLUE+5.70%
Monte Rosa doses first patient in Phase 2 MODeFIRe-1 trial of MRT-2359 plus apalutamide in mCRPCPUBT·1 day ago, 06:02 AMGLUE+5.70%
The Manufacturers Life Insurance Company Raises Stake in Monte Rosa Therapeutics, Inc. $GLUEMarket Beat·Aug 8 at 03:49 AMGLUE+5.70%
Zacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to "Hold"Market Beat·Aug 6 at 07:06 AMGLUE+5.70%GS-A-0.42%
Monte Rosa publishes corporate presentation on targeted protein degradation pipeline and molecular glue degradersPUBT·Aug 6 at 06:25 AMGLUE+5.70%
Monte Rosa activates Phase 2 MODeFIRe-1 trial of MRT-2359 plus apalutamide in metastatic prostate cancerPUBT·Aug 6 at 06:23 AMNVS+1.00%GLUE+5.70%
Monte Rosa Q2 FY26 net loss widens to $43.4 million; revenue falls 61.3% to $9 millionPUBT·Aug 6 at 06:14 AMGLUE+5.70%
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 4.1% After Analyst DowngradeMarket Beat·Aug 3 at 10:20 AMGLUE+5.70%
Why Monte Rosa Therapeutics (GLUE) Is Down 27.5% After Novo Nordisk’s ZEUS Trial Missed Its GoalSimplywall·Aug 1 at 02:13 AMNVO+2.46%GLUE+5.70%
Buy Rating Maintained on Monte Rosa as Diversified Degrader Pipeline and Novartis Partnership Offset ZEUS Cardiovascular SetbackTip Ranks·Jul 31 at 01:45 PMGLUE+5.70%NVS+1.00%
Monte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipelinebusinessinsider·Jul 31 at 01:16 PMBIOA+4.80%GLUE+5.70%
